Shiv Kumar Sarin, Manoj Kumar, George Lau, Zaigham Abbas et al.
Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available ...
Heléne Norder, Anne‐Marie Couroucé, Pierre Coursaget, José Manuel Echevarría et al.
Sequences of 234 complete genomes and 631 hepatitis B surface antigen genes were used to assess the worldwide diversity of hepatitis B virus (HBV). Apart from the described two subgenotypes each for A and F, also B, C, and D divided into four subgenotypes each in the analysis of complete genomes sup...
O Ohno, M. Mizokami, Rongrong Wu, Mohamed Saleh et al.
Recent studies have focused on whether different hepatitis C virus (HCV) genotypes are associated with different profiles of pathogenicity, infectivity, and response to antiviral therapy. The establishment of a simple and precise genotyping system for HCV is essential to address these issues. A new ...
J. Mellor, Edward C. Holmes, L M Jarvis, P.L. Yap et al.
Genotypes of hepatitis C virus (HCV) present within 104 samples from HCV-infected individuals from Africa, the Middle East, the Indian subcontinent and South-East Asia were identified by sequence comparisons in the core and NS-5 regions. Relatively short sequences (such as the 222 bp fragment of NS-...
Jack Stone, Hannah Fraser, Aaron G. Lim, Josephine G. Walker et al.
BACKGROUND: People who inject drugs (PWID) experience a high prevalence of incarceration and might be at high risk of HIV and hepatitis C virus (HCV) infection during or after incarceration. We aimed to assess whether incarceration history elevates HIV or HCV acquisition risk among PWID. METHODS: st...
Masao Omata, Tatsuo Kanda, Lai Wei, Ming‐Lung Yu et al.
The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus ...
Nicos Karasavvas, Erik Billings, Mangala Rao, Constance Williams et al.
The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp120 envelope (...
Verena Bihrer, Mireen Friedrich‐Rust, Bernd Kronenberger, Nicole Forestier et al.
OBJECTIVES: The liver contains large amounts of microRNA-122 (miR-122), whereas other tissues contain only marginal amounts of this miRNA. MicroRNAs have also been found to circulate in the blood in a cell-free form; their potential as readily accessible disease markers is currently evaluated. Here,...
Mamun Al‐Mahtab, Michel Bazinet, Andrew Vaillant
UNLABELLED: Previous in vivo studies have suggested that nucleic acid polymers (NAPs) may reduce circulating levels of HBsAg in the blood by blocking its release from infected hepatocytes and that this effect may have clinical benefit. NAP treatment, was evaluated in two clinical studies in patients...
Yasuhito Tanaka, Izumi Hasegawa, Takanobu Kato, Etsuro Orito et al.
There are two subtypes of hepatitis B virus genotype A (HBV/A) and they are provisionally designated Aa ("a" standing for Africa/Asia) and Ae ("e" for Europe). In a case-control study, 78 HBV/Aa, 78HBV/Ae, and 78HBV/D carriers from several countries were compared. The prevalence of HBe antigen (HBeA...
Fuminaka Sugauchi, Hiromitsu Kumada, Subrat A. Acharya, Santosh Man Shrestha et al.
Complete nucleotide sequences of 19 hepatitis B virus (HBV) isolates of genotype A (HBV/A) were determined and analysed along with those of 20 previously reported HBV/A isolates. Of the 19 HBV/A isolates, six including three from Japan and three from the USA clustered with the 14 HBV/A isolates from...
John D. Clemens, David A. Sack, Jeffrey R. Harris, J. Chakraborty et al.
Journal Article ABO Blood Groups and Cholera: New Observations on Specificity of Risk and Modification of Vaccine Efficacy Get access John D. Clemens, John D. Clemens Please address requests for reprints to Dr. John D. Clemens, Center for Vaccine Development, University of Maryland School of Medicin...
Hasan Ashraf, Nur Alam, Christian Rothermundt, Abdullah Brooks et al.
BACKGROUND: Viral hepatitis is a serious global public health problem affecting billions of people globally, and both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are rapidly spreading in the developing countries including Bangladesh due to the lack of health education, poverty, il...
Tatsuo Kanda, George Lau, Lai Wei, Mitsuhiko Moriyama et al.
In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection w...
Nicola Coppola, Loredana Alessio, Luciano Gualdieri, Mariantonietta Pisaturo et al.
Screening of undocumented migrants or refugees for hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections has been offered free of charge and free from bureaucratic procedures since 2012 at four primary-level clinical centres in Naples and Caserta, Italy. ...